Clinical Trial

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen the invasiveness of surgical resection. This randomized multicenter phase III trial is assessing whether preoperative chemotherapy improves oncologic outcomes of patients with locally advanced colon cancer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-02-02; most recent amendment 2026-02-10.
Status change: Recruiting → Active, Not Recruiting 2025-03-03
Status change: Not Yet Recruiting → Recruiting 2019-04-27
Trial Details
NCT Number NCT03426904
Lead Sponsor Kyungpook National University Hospital
Conditions Colon Cancer
Enrollment 708 participants
Start Date 2020-10-23
Primary Completion 2028-12-28 (estimated)
Study Completion 2031-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-11